AI Quick Summary

🔍 Meet the Residents Across Our SI Parks! 🔎@Bottneuro AG, a cutting-edge medtech startup founded in 2021, is making significant strides in improving the diagnosis and treatment of neurological diseases. Based at @Switzerland Innovation Park Basel on its Novartis Campus, the spin-off from the @Department of Biomedical Engineering at the @University of Basel focuses on non-invasive treatments for Alzheimer's disease and other neurological disorders.Electrical stimulation of specific brain regions is a promising treatment for neurological diseases such as Alzheimer's. Since everyone's brain is unique, stimulation caps need to be custom-made for each patient.Researchers at Bottneuro and @ETH Zurich have taken on this challenge, producing a prototype to showcase how Bottneuro’s process can be fully digitalized—from designing the helmet shape and positioning the electrodes to the 3D-printing process for fabrication.ETH Professor @Mirko Meboldt assists Swiss SMEs in finding the right technology to maintain their competitive edge. “Companies often come to us because they want to stay competitive but aren’t sure if they could benefit from new technologies like artificial intelligence,” says Professor Meboldt.After three years of development, Bottneuro’s Miamind®, the patient-specific neurostimulator for non-invasive brain stimulation, has been officially registered with Swissmedic and the British regulatory authority.🌐 Discover more about Bottneuro’s collaboration with ETH: https://ethz.ch/en/news-and-events/eth-news/news/2024/06/globe-how-smes-benefit-from-eth-zurich.html #SwitzerlandInnovation #WhySwitzerland #Neuroscience #Healthcare #Medtech

Post Metadata

• Author: Switzerland Innovation Digital
• Published Date: 7/25/2024 12:37:23 PM
• Modified Date: 9/24/2024 12:32:51 PM

Post Description

🔍 Meet the Residents Across Our SI Parks! 🔎

@Bottneuro AG, a cutting-edge medtech startup founded in 2021, is making significant strides in improving the diagnosis and treatment of neurological diseases. Based at @Switzerland Innovation Park Basel on its Novartis Campus, the spin-off from the @Department of Biomedical Engineering at the @University of Basel focuses on non-invasive treatments for Alzheimer's disease and other neurological disorders.

Electrical stimulation of specific brain regions is a promising treatment for neurological diseases such as Alzheimer's. Since everyone's brain is unique, stimulation caps need to be custom-made for each patient.

Researchers at Bottneuro and @ETH Zurich have taken on this challenge, producing a prototype to showcase how Bottneuro’s process can be fully digitalized—from designing the helmet shape and positioning the electrodes to the 3D-printing process for fabrication.

ETH Professor @Mirko Meboldt assists Swiss SMEs in finding the right technology to maintain their competitive edge. “Companies often come to us because they want to stay competitive but aren’t sure if they could benefit from new technologies like artificial intelligence,” says Professor Meboldt.

After three years of development, Bottneuro’s Miamind®, the patient-specific neurostimulator for non-invasive brain stimulation, has been officially registered with Swissmedic and the British regulatory authority.

🌐 Discover more about Bottneuro’s collaboration with ETH: https://ethz.ch/en/news-and-events/eth-news/news/2024/06/globe-how-smes-benefit-from-eth-zurich.html

#SwitzerlandInnovation #WhySwitzerland #Neuroscience #Healthcare #Medtech